Stem cells and plasticity of skeletal muscle cell differentiation: potential application to cell therapy for degenerative muscular diseases.
Stem cells and plasticity of skeletal muscle cell differentiation: potential application to cell therapy for degenerative muscular diseases.
复制标题
DOI：
10.2217/17460751.2.3.243
复制
发表时间：
2007-05
影响因子：
2.7
通讯作者：
T. Endo
中科院分区：
文献类型：
--
作者：
T. Endo
退行性肌肉疾病，例如肌营养不良症，一直是再生细胞疗法的代表性目标。尽管卫星细胞在肌肉损伤后本质上发生的骨骼肌再生中发挥着核心作用，但它们在细胞治疗中的应用面临着困难。预期适用于细胞疗法的其他干细胞包括肌肉驻留干细胞和非肌肉驻留干细胞。此外，骨骼肌的去分化细胞可能为细胞治疗提供独特的系统。终末分化肌管在某些实验条件下具有分化和去分化的可塑性，包括表达SV40大T抗原或同源盒基因Msx1。去分化细胞表现出转分化为多种间充质来源细胞的多能性。此外，用药物处理的成纤维细胞或未分化的成肌细胞获得多能性。这些细胞可能为细胞治疗打开新的大门。
Degenerative muscular diseases, such as muscular dystrophies, have been the representative targets of regenerative cell therapy. Although satellite cells play central roles in skeletal muscle regeneration that intrinsically occurs after muscle injury, their application to cell therapy is confronted by difficulties. Other stem cells expected to be applicable to cell therapy include muscle-resident stem cells and nonmuscle-resident stem cells. Moreover, dedifferentiated cells of skeletal muscle might provide unique system for cell therapy. Terminally differentiated myotubes have plasticity of differentiation and dedifferentiate under certain experimental conditions, including the expression of SV40 large T antigen or the homeobox gene Msx1. The dedifferentiated cells exhibit multipotency to transdifferentiate into multiple mesenchymal origin cells. In addition, fibroblasts or undifferentiated myoblasts treated with a drug acquire multipotency. These cells may open new doors in cell therapy.